



Certificate of Analysis CANNABIS Flos

Batch: 25031317

Product	Peace Naturals 29/1 GC
Country	Germany
Manufacturing license No.:	DE RP 01 MIA 2022 0054
Potency	Δ^9 -Tetrahydrocannabinol approx. 29%; Cannabidiol $\leq$ 1%
Dosage form	Cannabis flowers, dried; cultivar: GMO Cookies
Pack size	10g pouches
Batch	25031317-01001; -02001; -03001

Manufacturing date:	05.06.2025
----------------------------	------------

Test	Method	Specification	Result	Complies
Identification A	EP 3028	Complies with the description of the monograph	Complies	YES
Identification B	EP 3028	Complies with the description of the monograph	Complies	YES
Identification C	EP 3028 (TLC)	Complies with the description of the monograph	Complies	YES
Assay	EP 3028 (HPLC)	CBD total: $\leq$ 1.0% CBN: $\leq$ 1.0% THC total: 26.1% – 31.9%	< 0.1% < 0.1% 29.5%	YES
Foreign matter	EP 3028	$\leq$ 2.0% No seeds No leaves > 1.0 cm	< 2 % Complies Complies	YES
Loss on drying	EP 3028	$\leq$ 12.0%	7.6%	YES
Total Ash	EP 2.4.16	$\leq$ 20%	8.1%	YES
Pesticides	EP 2.8.13	Complies with the requirements EP 2.8.13	n.n.	YES
Aflatoxins	EP 2.8.18	B1: $\leq$ 2 μ g/kg Sum B1, B2, G1, G2: $\leq$ 4 μ g/kg	n.n. n.n.	YES
Ochratoxin A	EP 2.8.22	$\leq$ 20 μ g/kg	n.n.	YES
Heavy metals analysis	EP 2.4.27	Arsenic: $\leq$ 0.2 ppm Cadmium: $\leq$ 0.3 ppm Lead: $\leq$ 0.5 ppm Mercury: $\leq$ 0.1 ppm	n.n. n.n. n.n. n.n.	YES
Microbiological purity*		<i>EP 5.1.8C</i>		YES
<i>TAMC</i>	EP 2.6.12	$\leq$ 500 000 cfu/g	13 000 cfu/g	
<i>TYMC</i>		$\leq$ 50 000 cfu/g	14 000 cfu/g	
<i>Bile tolerant gram neg. bacteria</i>	EP 2.6.31	$\leq$ 10 000 cfu/g	< 10 cfu/g	
<i>Escherichia coli</i>		<i>absent / 1 g</i>	<i>absent / g</i>	
<i>Salmonella species</i>		<i>absent / 25 g</i>	<i>absent / 25g</i>	

n.n. = below limit of quantitation

Examined by: QSI GmbH, Flughafendamm 9a, 28199 Bremen

Expiry date	06.09.2025
--------------------	-------------------

I hereby declare that this batch of the medicinal product has been manufactured and tested in compliance with the applicable GMP regulations and in accordance with the master documents approved by the client and has been tested in compliance with recognized pharmaceutical regulations pursuant to § 6 No. 3 ApBetrO and is hereby released for marketing pursuant § 16 AMWHV.

All starting materials and intermediate products used have been tested and were approved.



10.06.2025



Date / Signature Qualified Person

ADREXpharma GmbH, Jakob- Hasslacher- Str. 4 56070 Koblenz
HRB 26108, Koblenz

Steuer Nummer 22/650/01532
VAT Nummer DE 815 754 017

T +49 261 450 98 20
F +49 261 450 98 210
info@adrexpharma.com
www.adrexpharma.com
Gerichtsstand: Koblenz

Sparkasse Koblenz
IBAN: DE93 5705 0120 0000 2710 80
BIC: MALADE51KOB

GF: Nicole Broockmann